Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-5.19Last Year’s EPS
5.3Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -11.48%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a balanced outlook with strong neuroscience performance and R&D progress countered by declining oncology sales and legal settlement impacts. Potential tariff issues could also pose future challenges.Company Guidance
In the first quarter of 2025, Jazz Pharmaceuticals reported strong financial performance, driven by a total revenue of $898 million, with their neuroscience portfolio showing impressive growth. Xywav's net product sales increased by 9% year-over-year, with 14,600 active patients by the end of the quarter, including 125 narcolepsy and 325 IH patients. Epidiolex saw a 10% increase in revenue, reaching approximately $218 million. The company's oncology portfolio faced near-term challenges, with Rylaze experiencing an 8% decline in sales due to changes in pediatric treatment protocols. Despite this, Jazz anticipates growth potential with three regulatory approvals on the horizon, including Dordaviprone and Zepzelca. The company maintains confidence in its top-line revenue guidance and updated its financial guidance to account for the Chimerix acquisition and litigation settlement charges.Strong Commercial Performance in Neuroscience
Xywav grew 9% year-over-year, remaining the number one branded treatment for narcolepsy. Epidiolex revenues increased 10% year-over-year, with expectations to reach blockbuster status in 2025.
R&D Pipeline Progress
Significant advancements include a supplemental new drug application for Zepzelca, a positive CHMP opinion for zanidatamab in Europe, and the acquisition of Chimerix, enhancing Jazz's rare oncology presence.
Financial Stability and Guidance
Jazz reported $898 million in total revenues for Q1 2025 and affirmed its total revenue guidance for 2025 at $4.15 billion to $4.4 billion.
Potential Regulatory Approvals
Upcoming potential approvals for Dordaviprone, Zepzelca expansion, and zanidatamab in Europe, with significant data presentations expected at ASCO.
---
JAZZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JAZZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $111.17 | $101.44 | -8.75% |
| Feb 25, 2025 | $139.67 | $144.17 | +3.22% |
| Nov 06, 2024 | $111.55 | $119.08 | +6.75% |
| Jul 31, 2024 | $110.25 | $114.38 | +3.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Jazz Pharmaceuticals (JAZZ) report earnings?
Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Jazz Pharmaceuticals (JAZZ) earnings time?
Jazz Pharmaceuticals (JAZZ) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAZZ EPS forecast?
JAZZ EPS forecast for the fiscal quarter 2025 (Q2) is -5.19.
---